GMJ Briefs
What Hepatitis B Patients Should Know About Emerging Treatment Options
Bepirovirsen offers chronic hepatitis B patients a new treatment option with 96% viral suppression and a favorable safety profile.
What Readers Should Know About the XPRIZE Healthspan Longevity Competition
Three key insights on longevity research: functional restoration is the goal, multiple intervention modalities show greatest promise, and expert caution…
What XPRIZE Healthspan Means for Understanding Aging Research and Consumer Safety
XPRIZE Healthspan demonstrates the difference between evidence-based longevity research and unproven anti-aging products flooding the consumer market.
What Cambridge’s Organoid Breakthrough Means for Treating Nerve Damage
Lab-grown organoids reveal that adult nerve damage can be reversed using thyroid hormones and gene-targeted interventions.
What Clinicians Need to Know About Bepirovirsen’s Novel Hepatitis B Mechanism
Bepirovirsen's antisense mechanism offers clinicians a novel approach to achieve functional cure in chronic hepatitis B beyond traditional viral suppression.
What Clinicians Need to Know About Bepirovirsen’s Novel Approach to Hepatitis B
Bepirovirsen's antisense mechanism targets functional cure through HBsAg reduction, offering clinicians a novel approach beyond conventional viral suppression.
Three Critical Safety Issues With GLP-1 Microdosing You Need to Know
Three key safety concerns about GLP-1 microdosing: lack of clinical evidence, variable compounded formulation quality, and need for medical supervision.
23% Faster Cognitive Decline Associated with Regular Table Salt Addition, New Study Shows
Brazilian study documents 23% faster cognitive decline among older adults who regularly add table salt to meals over 24 months.